Author archives: Mark Vickery

Results of a trial developed with Cambridge, MA-based Ridgeback Biotherapeutics are positive for an oral antiviral treatment for Covid-19.

We see supply constraint issues meeting with an unsure near-term future with the budget of the federal government, along with a Fed body looking close…

Both Nike and Costco beat bottom-line estimates in their subsequent quarters, but struggled to match on the top-line.

The dot-plot for raising interest rates looks fairly mild across the board, which of course would follow the tapering process.

Housing Starts came in at 1.62 million, higher than the 1.55 million estimate, which happened to be the headline number for July.

The “Chinese contagion” trade did deplete all sectors for the day; almost nothing survived this 2%+ knee-capping.

The Dow dropped nearly 300 points, -0.83% on the day. The S&P 500 and Nasdaq were pretty close: -0.57% and -0.45%, respectively.

For the Dow and the S&P, they have each finally snapped a five-session losing streak.

Lululemon (LULU) results were better than expected after hours, with $1.65 per share easily outperforming the $1.21 Zacks consensus.

The Nasdaq’s intra-day highs have been even higher than the record-high closes.